Fig. 2.

Development of cell type-specific tau inclusions after injection of CBD-Tau- or DSAD-Tau-enriched protein extracts into the brains of PS19 mice. a, c, e AT8-positive oligodendroglial inclusions developed in the fimbria of the hippocampus on the injected side at 1 month after the injection of CBD-Tau. b, d, f AT8-positive inclusions developed in the perikarya of neurons of the hippocampus of DSAD-Tau-injected mice. c A higher magnification of the square boxed area in (a) is shown in (c) demonstrating AT8-positive tau inclusions in many oligodendrocytes of the fimbria (c). The inset in (c) shows a detail of the oligodendrocytes indicated by the black arrows. d A higher magnification of the square boxed area in (b) is shown in (d) demonstrating the absence of tau inclusions in the oligodendrocytes of the fimbria (d) which contrasts with the CBD-Tau-injected mice. e Higher magnification of the rectangular boxed area in (a) demonstrating only rare intraneuronal inclusions in the CA3 region of the hippocampus (e). In f, where a higher magnification of the rectangular boxed area in (b) is depicted, there is abundance of perikaryal AT8 inclusions in CA3 of the hippocampus. Scale bar, upper row 500 μm; middle and bottom rows 50 μm